Dynophore:Dynamische Pharmakophore by Sydow, Dominique
LEBENSWISSENSCHAFTLICHE FAKULTA¨T
INSTITUT FU¨R BIOLOGIE
MASTERARBEIT
ZUM ERWERB DES AKADEMISCHEN GRADES
MASTER OF SCIENCE
Dynophore:
Dynamische Pharmakophore
Implementierung der Generierung von Pharmakophoren
auf der Basis von Moleku¨ldynamik-Trajektorien
und ihre graphische Darstellung
Dynophores:
Novel Dynamic Pharmacophores
Implementation of Pharmacophore Generation
Based on Molecular Dynamics Trajectories
and Their Graphical Representation
vorgelegt von
Dominique Sydow
angefertigt in der Arbeitsgruppe
Computergestu¨tztes Wirkstoffdesign
Pharmazeutische und Medizinische Chemie
Institut fu¨r Pharmazie
Freie Universita¨t Berlin
30. November 2015
Supervision
Internal Supervision
Prof. Edda Klipp
Theoretische Biophysik
Institut fu¨r Biologie
Humboldt-Universita¨t zu Berlin
External Supervision
Prof. Gerhard Wolber
Computergestu¨tztes Wirkstoffdesign
Institut fu¨r Pharmazie
Freie Universita¨t Berlin
Acknowledgements
First of all, I want to thank Prof. Gerhard Wolber for welcoming me in his group at the
Freie Universita¨t Berlin, and giving me the chance to combine Java programming with
the interesting field of computer-aided drug design. I am very grateful for his structured
guidance and friendly support during my project.
I acknowledge Christin Rakers and Dr. Marcel Bermudez for giving me the opportunity
to test my program with molecular dynamics simulations for their projects SULT1E1
and M2AChR, respectively. Discussions about the results and potential applications
constantly improved my work.
I thank the whole group of Prof. Wolber for their enthusiasm about dynophores, and
their suggestions and discussions on my project.
Prof. Gerhard Wolber, Christin Rakers, Dr. Marcel Bermudez and Dr. Je´re´mie Mortier
improved my written master thesis by valuable suggestions and advice.
Furthermore, I want to thank the Frauenfo¨rderung of the Fachbereich Biologie, Chemie,
Pharmazie at the Freie Universita¨t Berlin for supporting my visit at the Summer School
Drug Design in Vienna. This conference was a great opportunity for me to learn a lot
about techniques in drug design, and to present and discuss my work outside of my group.
I am obliged to the Friedrich-Ebert-Stiftung for their promotion and financial support
during my Bachelor and Master studies.
I am thankful to Ferdinand Krupp for his support and confidence during my master
studies, as well as his never-ending enthusiasm for scientific discussions.
Last but not least, I am very grateful to Prof. Edda Klipp for her supervision and
evaluation of my master thesis on behalf of the Humboldt-Universita¨t zu Berlin.
Abstract
In medicinal chemistry and drug discovery, pharmacophore modelling has become a well
established method for molecular design. A 3D pharmacophore model represents the
ensemble of universal steric and chemical features that stand for a specific mode of bind-
ing. Currently, these pharmacophores are created from a multi-conformational ligand set
(ligand-based drug design) or from a ligand-target complex (structure-based drug design).
However, classical pharmacophore models only allow a static view on a single ligand-target
conformation. The aim of the presented study was to develop pharmacophore models that
represent conformational flexibility derived from molecular dynamics (MD) simulations.
Therefore, pharmacophore features from the MD trajectory frames are grouped into so-
called superfeatures by their feature type and involved atoms on ligand-site. Subsequently,
these superfeatures and their environmental interaction partners are statistically and se-
quentially analysed in terms of their occurrence and interaction distance. These dynamic
pharmacophores are termed dynophores, and graphically represented as feature point
clouds for superfeature space analysis. Dynophores potentially enhance the predictive
power of 3D pharmacophores, and serve as powerful analysis and validation tool for the
evaluation of pharmacophores, ligand-target interaction patterns and MD simulations.
Dynophore generation and analysis were implemented as DynophoreApp program within
the ilib/LigandScout framework, a Java-based software for in silico drug discovery.
Zusammenfassung
In der medizinischen Chemie und Wirkstoffforschung haben sich Pharmakophormodelle
als wichtige Methode fu¨r molekulares Design etabliert. Ein 3D Pharmakophormodell
repra¨sentiert ein Ensemble von universellen sterischen und chemischen Eigenschaften (Fea-
tures), die einen spezifischen Bindungsmodus beschreiben. Diese Pharmakophore werden
auf der Grundlage eines Sets von Liganden in verschiedenen Konformationen (Liganden-
basiertes Wirkstoffdesign) oder aus einem Liganden-Target-Komplex (Struktur-basier-
tes Wirkstoffdesign) erstellt. Allerdings erlauben klassische Pharmakophore lediglich
eine statische Sicht auf eine einzige Liganden-Target-Konformation. Ziel dieser Arbeit
war die Entwicklung eines Pharmakophormodells, das die Konformationsflexibilita¨t aus
Moleku¨ldynamik (MD)-Simulationen abbildet. Dafu¨r werden die Pharmakophor-Features
fu¨r jeden Trajektorienzeitschritt in so genannte Superfeatures gruppiert. Die Gruppierung
erfolgt anhand des Feature-Typs und der Ligandenatome, welche an dem Feature beteiligt
sind. Nachfolgend werden die Superfeatures und ihre Interaktionspartner statistisch und
sequentiell hinsichtlich ihres Auftretens und dem Abstand zwischen den Interaktion-
spartnern ausgewertet. Diese dynamischen Pharmakophore werden Dynophore genannt
und graphisch als Feature-Punktwolke fu¨r eine ra¨umlichen Analyse der Superfeatures
dargestellt. Dynophore haben das Potential, die Vorhersagekraft von 3D Pharmakophoren
zu verbessern und dienen gleichzeitig als Analyse- und Validierungswerkzeug zur Bewer-
tung von Pharmakophoren, Liganden-Target-Interaktionsmustern und MD-Simulationen.
Das Programm DynophoreApp wurde zur Generierung und Analyse von Dynophoren im
Rahmen des ilib/LigandScout-Frameworks implementiert, einer Java-basierten Software
fu¨r in silico Wirkstoffdesign.
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1 INTRODUCTION
1 Introduction
1.1 Computer-Aided Drug Design
Computer-aided drug discovery (CADD) has evolved to an important method during the
development of therapeutically relevant small molecules. Due to its more targeted and
rational approach when compared to traditional high-throughput screening and combi-
natorial chemistry, CADD aims to significantly decrease the number of compounds nec-
essary for experimental screening while increasing the hit rate of novel drug molecules. It
not only intends to explain the molecular basis of therapeutic activity, but also to predict
possible derivatives that would improve activity. In the drug discovery pipeline (Figure 1),
computational methods are usually used to (i) filter predicted active compounds from
large compound libraries for experimental testing, (ii) optimise lead compounds by in-
creasing its affinity or improve properties including absorption, distribution, metabolism,
excretion, and toxicity (ADMET), and (iii) design novel compounds [1].
Target identification
Computer-aided drug discovery
(CADD)
Structure-based CADD
Target structure information
Ligand docking De novo design
MD Pharmacophore modelling
Ligand-based CADD
Ligand structure information
QSAR Pharmacophore modelling
Ligand-based virtual screening
Lead component
identification and optimisation
Drug candidate
for experimental testing
Figure 1: Computer-aided drug discovery (CADD) pipeline: A therapeutically
relevant target is identified, and a structure- or ligand-based approach is selected for
drug discovery, depending on the availability of structural information. After successful
identification of multiple lead compounds, several cycles of lead optimisation result in
one or more drug candidates [1].
1
1 INTRODUCTION
A target of therapeutic interest is selected and enters the CADD pipeline (Figure 1): De-
pending on the availability of structural information on target and ligand, a structure- or
ligand-based approach is selected for drug discovery. In ligand-based drug design on the
one hand, information about ligand structures and their associated activity can be de-
scribed using quantitative structure-activity relationship (QSAR) models or summarised
using pharmacophore models for ligand-based virtual screening. In structure-based drug
design on the other hand, information about the target structure is used for ligand dock-
ing, de novo design of ligands, molecular dynamics (MD) studies and/or pharmacophore
modelling of ligands bound to a target. After successful identification of bio-active com-
pounds, several cycles of lead optimisation result in one or more drug candidates.
In the study presented, structure-based techniques of pharmacophore modelling and MD
studies are combined to an extended pharmacophore model including previously missing
information on ligand-target dynamics and conformational states.
1.2 Ligand-Target Interaction Mapping Using Molecular Dy-
namics
Macromolecular structures are mainly explored using X-ray diffraction of crystallised
proteins. However, this technique only provides a static conformation, one snapshot of
multiple possible conformations. Flexibility of a molecular system can be derived from
nuclear magnetic resonance (NMR) experiments, which show an ensemble of conforma-
tions of a system, but which are also very challenging to interpret for larger systems.
Hence, complementary tools for the investigation of target and ligand binding dynamics
are needed. In silico MD simulations can be used to investigate conformational dynamics
of a protein-ligand complex. Such simulations can yield dynamic information of a system
on an atomic level, not only in terms of protein dynamics and its configuration states
but also in terms of target-ligand interactions. Thus, MD has emerged as an important
technique for drug design [2].
Several different MD-based approaches for protein-ligand interaction mapping are de-
scribed in literature and conceptually summarised here:
(i) Multiple-copy simultaneous search (MCSS) generates functionality maps, which de-
scribe favourable ligand binding derived from MD simulations of functional frag-
ments that are simultaneously and randomly placed on the protein surface [3].
(ii) In the locally enhanced sampling (LES) method, ligand conformations are sampled
from a simulation with several ligand copies that do not interact with each other
but do interact with the environment [4].
(iii) The relaxed complex method (RSC) docks whole ligands to an ensemble of target
conformations derived from MD simulations with subsequent rescoring [5, 6, 7].
(iv) The lambda dynamics method is another multiple-copy method for speeding up
free-energy calculations. Multiple ligands are simultaneously located in the receptor
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binding site, and the barriers for conformational transitions are lowered. This allows
each ligand to further explore orientational and conformational space [8].
(v) Structure-based pharmacophore models represent the ensemble of universal steric
and chemical features of a ligand within its structural environment. In MD-based
static pharmacophore modelling, also referred to as dynamic pharmacophore mod-
elling, a pharmacophore model is created from several ligand-target conformations
derived from MD simulations. Such approaches will be discussed in the following
in more detail and form the starting point of this study.
MD-based static pharmacophores. In literature, several approaches include MD
simulations in the generation of static pharmacophore models. These approaches are
generally composed of three steps:
1. Select structural conformations from MD trajectories: MD simulations of the tar-
get with or without ligand are conducted, and representative conformations are
generated with different clustering methods.
2. Define pharmacophore models for each conformation: Pharmacophore features for
each selected conformational snapshot are defined with various tools and methods.
These methods include simulating probe molecule positions at the active site [9],
decision-based positioning of probes in box grids covering the active site [10], or
the use of Metropolis configurational sampling for fixed target and probe molecules
[11]. Those methods were used to create MD-based static pharmacophores for HIV-
1 integrase [9, 10, 11]. Other probing techniques use LUDI interaction maps [12],
or molecular interaction field analysis [13]. Furthermore, docking can serve as basis
for pharmacophore modelling, such as probe docking followed by energy mapping,
clustering and ranking [14, 15], or ligand screening against all selected conforma-
tional snapshots using ensemble docking [16, 17] with subsequent pharmacophore
generation for docked ligand hits.
3. Superpose all pharmacophore models, and decide on a generalised pharmacophore
model: An MD-based static pharmacophore model is generated by superposition of
all pharmacophores per conformational snapshot and rule-based selection of com-
mon features.
However, these MD-based static pharmacophore models represent a selection of confor-
mational states but not the dynamic nature of the MD trajectory. Thus, the aim of
this work was to include MD-based information on flexibility of a system in a dynamic
pharmacophore modelling approach.
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1.3 Aim of This Work
This work aimed at including conformational and dynamic information derived from MD
simulations in one single dynamic pharmacophore model. Therefore, an automated work-
flow for integrated dynamic pharmacophore generation, analysis and representation was
implemented using the application programming interface (API) of the ilib/LigandScout
framework. This novel dynamic pharmacophore is termed dynophore and the associated
program DynophoreApp. This approach allows the usage of whole MD trajectories or
user-defined trajectory intervals, and summarises LigandScout three-dimensional (3D)
pharmacophores for each trajectory snapshot in one comprehensive dynophore. Hence,
dynophores extend classic 3D pharmacophores with statistical and sequential informa-
tion about possible conformational states derived from MD simulations. In such a way,
the static view of pharmacophores is transferred to a dynamic one with dynophores.
4
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2 Methods
2.1 Pharmacophore Modelling
In CADD, the description of drug-target interactions with pharmacophores has evolved
to a well-established method. A general definition for the term pharmacophore was
published in 1998 by a IUPAC working party [18]:
A pharmacophore is the ensemble of steric and electronic features that is
necessary to ensure the optimal supramolecular interactions with a specific
biological target structure and to trigger (or to block) its biological response.
A pharmacophore does not represent a real molecule or a real association of
functional groups, but a purely abstract concept that accounts for the common
molecular interaction capacities of a group of compounds towards their tar-
get structure. The pharmacophore can be considered as the largest common
denominator shared by a set of active molecules.
Hypothetical models such as pharmacophores must be (i) selective enough to filter active
from inactive compounds, (ii) universal enough to find ligands as novel drug candidates,
and (iii) suitable to automatically match large compound libraries. A common approach
is to derive a model from distinct ligands in order to represent the specific mode of
interaction by including or excluding descriptive chemical features. A classification of
abstraction layers for chemical features is described in Table 1. By restricting general
chemical feature definitions, the number of features increases at the cost of comparability.
However, only comparable pharmacophores are sufficiently universal, and can represent
a mode of action instead of a set of already existing ligands.
Layer Classification Example
4 chemical functionality
without geometric constraint
ionisable area,
lipophilic contact
S
p
ec
ifi
ci
ty
U
n
iversality
3 chemical functionality
with geometric constraint
hydrogen bond donor,
acceptor
2 molecular graph descriptor
without geometric constraint
atom, bond
1 molecular graph descriptor
with geometric constraint
atom, bond
Table 1: Classification of abstractions layers for chemical features: the lower the
abstraction level, the higher the specificity/selectivity and the lower the universality/
comparability of a chemical feature [19].
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2.2 3D Pharmacophores in LigandScout
Using the pharmacophore modelling software LigandScout [20, 21], 3D pharmacophores
can either be developed by (i) ligand-based drug design, starting from a set of ligands that
are known to similarly bind to the same target, or by (ii) structure-based drug design,
investigating specific ligand-target interactions if the complex structure is available.
In LigandScout, a molecular system is interpreted as molecular environment which is com-
posed of (i) a core molecule, consisting of the ligand to be examined, and of (ii) a macro-
molecule consisting of the rest, i.e. the target, cofactors, water molecules, and ions.
Structure-based 3D pharmacophores are generated from the interactions between core
molecule and macromolecule.
2.2.1 Definition and Representation
3D pharmacophores in LigandScout consist of chemical features that are classified as
abstraction layers 3 and 4 (Table 1). Pharmacophore features are visualised by point and
vector features, respectively (Table 2): Point features are defined as 3D centre with scalar
tolerance, and include hydrophobic (yellow sphere), aromatic (blue torus), positive (red
star) and negative (blue star) ionisable areas. Hydrogen bond donors (green arrow) and
acceptors (red arrow) belong to the vector features group [19].
Hydrogen bond acceptor (HBA)
Hydrogen bond donor (HBD)
Hydrophobic area (H)
Negative ionisable (NI)
Positive ionisable (PI)
Aromatic ring (AR)
Figure 2: Chemical feature types in LigandScout: Point features include hydropho-
bic (yellow sphere), aromatic (blue torus), positive (red star) and negative (blue star)
ionisable features. Vector features include hydrogen bond donors (green arrow) and ac-
ceptors (red arrow). By default feature tolerances range from 1.0 to 1.5 A˚.
2.2.2 Data Structure
The ilib/LigandScout framework has been developed in the programming language Java.
3D pharmacophores are represented as Pharmacophore objects that contain all pharma-
cophore features as ChemicalFeature3D objects.
Pharmacophore class. The class Pharmacophore consists among others of a set of
ChemicalFeature3D objects (TreeSet<ChemicalFeature3D> features) which represent
6
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features such as hydrogen bond donors/acceptors or hydrophobic contacts. During phar-
macophore generation, all potential features are generated separately on ligand- and
target-site with a subsequent search for complementary features which will be saved as
pharmacophore feature.
ChemicalFeature3D class. The class ChemicalFeature3D represents a pharmacophore
feature, such as a hydrogen bond donor or acceptor, a hydrophobic area, or an aromatic
ring. The ChemicalFeature3D class consists of
• the feature type (String name), such as a hydrogen bond donor,
• all atom serials on ligand-site that are involved in the feature (Collection<Atom>
involvedAtoms),
• the coordinates for the geometric centre of the feature atoms (double[] array3d),
and
• all atom serials on target-site that are involved in the feature (Set<Atom> envAtoms).
2.2.3 PML/PMZ File Format
The Pharmaceutical Markup Language (PML) is a XML-based file format storing infor-
mation about ligand, target and pharmacophore in LigandScout. The compressed PML
format is called PMZ. The PML format contains the tag <MolecularEnvironment>,
describing the molecular environment in LigandScout, which is composed of
• <CoreMolecule>, information about atoms and bonds of the ligand,
• <Environment>, information about atoms and bonds of the ligand environment,
consisting of the target, water and ions, and
• <Pharmacophore>, optional, the pharmacophore description, consisting of infor-
mation about its features, such as feature type and involved atoms on ligand and
environmental site.
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2.3 Molecular Dynamics Simulations
Molecular Dynamics (MD) trajectories represent the possible evolution of a molecular
system over time. Hence, MD simulations yield information on dynamics of a molecular
system on an atomic level, not only in terms of protein dynamics and its configuration
states but also in terms of target-ligand interactions.
2.3.1 Molecular Dynamics Force Fields
In MD, the possible evolution of a molecular system over time is calculated based on its
force-field approximated potential energy. The principle of the MD trajectory calcula-
tion lies in the numerical integration of the Newtonian equations of motion. The force
acting on a specific atom is calculated iteratively by taking the derivative of the potential
energy function with respect to its position. The potential energy contains (i) covalent
interactions, such as bond stretching, bond angle bending, and dihedral bending, and
(ii) non-covalent interactions, such as van der Waals and Coulombic terms (Equation 1).
The potential energy function V (ri,...,N) is described as function of the position r for N
particles (Equation 2) [22].
Vtotal =
∑
bonds
Vb +
∑
angles
Vθ +
∑
dihedrals
Vφ︸ ︷︷ ︸
Vcovalent
+
N∑
i=1
N∑
j=i+1
(VvdW + VCoulomb)︸ ︷︷ ︸
Vnon-covalent
(1)
V (ri,...,N) =
∑
bonds
ki
2
(li − li,0)2 +
∑
angles
ki
2
(θi − θi,0)2 +
∑
dihedrals
Vn
2
(1 + cosnω − γ)
+
N∑
i=1
N∑
j=i+1
(
4ij
(
(
σij
rij
)12 − (σij
rij
)6
)
+
qiqj
4pi0rij
)
(2)
The potential energy function with its associated parameters is called force field.
2.3.2 DCD File Format
The DCD format is a binary FORTRAN file, containing the information about the MD
trajectory for each saved time step of the simulation. This file format can be generated
from any MD program output in e.g. VMD (Visual Molecular Dynamics) [23], an MD
visualisation and analysis program.
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3 Workflow: Dynophores
Structure-based 3D pharmacophores in LigandScout are generated from a static struc-
ture conformation, e.g. from the crystal structure or a snapshot of an MD simulation.
Therefore, this pharmacophore only represents a static view on the interaction between
target and ligand. Dynophores aim at extending classic 3D pharmacophores in Lig-
andScout with statistical and sequential information about conformational states of a
molecular system derived from MD simulations. The dynophore program DynophoreApp
was implemented using the API of the ilib/LigandScout framework [20, 21]. The program
automatically generates a pharmacophore for each snapshot of a given MD simulation
and processes its features pursuing the following principle (Figure 3): Each feature is
grouped into so-termed dynophore superfeatures. If a feature of the same type (e.g hy-
drogen bond donor or hydrophobic area) and the same involved atoms on ligand-site
reoccurs over time, these features will build one group, the superfeature, to be monitored
in its behaviour over the whole trajectory.
3.1 Dynophore Input
Dynophores include information on all LigandScout 3D pharmacophores generated for
each frame of a MD trajectory. For a molecular system of interest, the dynophore gen-
erating program DynophoreApp requires (i) the assignment of all atoms to ligand- or
target-site in LigandScout, and (ii) the MD trajectory to be analysed in terms of ligand-
target-interactions as input (Figure 3).
LigandScout topology: PMZ format. For PMZ generation (PMZ definition in Sec-
tion 2.2.3), the PDB structure of interest has to be loaded in the structure-based view of
LigandScout, all atoms have to be assigned appropriately to the ligand (core molecule) or
environmental (macromolecule) side, and proper bond interpretations have to be checked.
The assignments can be saved as PMZ via File → Save as File.
MD trajectory: DCD format. The trajectory has to be prepared as follows before
being saved as DCD (DCD definition in Section 2.3.2): (i) If the atoms of a molecular
system are not all in one periodic box, but distributed over various boxes, they all have
to be wrapped into a chosen image. In VMD, the pbc wrap function can be used to
handle periodic boundary conditions. (ii) Since ligand movement and interaction with
its environment are to be analysed, it is important for the dynophore visualisation that
the trajectory is aligned on the environment of interest, e.g. the whole target molecule
in the first trajectory frame. VMD provides a root mean square deviation (RMSD)
alignment tool, accessible via VMD Main Menu → Extensions → Analysis → RMSD
Trajectory Tool. This step is crucial for the spatial analysis of the graphical dynophore
representation.
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3.2 Dynophore Generation
DynophoreApp loads (i) the molecular environment from the PMZ file to define the core
molecule (e.g. ligand), and macromolecule (e.g. target, cofactor, water or ions), and (ii)
all trajectory frames from the DCD file.
For each frame ti, the molecular environment is updated with the information given in
the current frame from the MD trajectory, e.g. atom positions. For this configuration of
the molecular system, a LigandScout 3D pharmacophore is generated. For each feature
fj of this pharmacophore, information about the interactions between ligand and its
environment is saved in the following manner:
1. A superfeature is derived from feature fj: The superfeature is defined by its (i)
feature type and (ii) involved atoms on ligand-site. If this superfeature already
occurred during the trajectory, information about feature fj is added to it. If not,
information about feature fj is saved with the new superfeature. The superfeature,
containing feature type and involved atoms, additionally gains the information
about the frame it occurred in and the position of feature fi. Visualised in 3D,
features belonging to the group superfeature will therefore build a point cloud.
2. Information about the interaction between ligand and its environment is gathered.
For feature fj, all interaction (=environmental) partners on target-site are saved
as follows: Each environmental partner is defined by its atoms interacting with the
ligand. For each superfeature, all environmental partners over the whole trajectory
are saved storing their occurrence or non-occurrence per frame. Additionally, the
interaction distance is saved for all interactions over the trajectory for interaction
quality assessment.
3.3 Dynophore Analysis Output
Generated information about dynophores (Section 3.2) is graphically represented and
processed for feature and interaction pattern analysis as shown below:
Graphical representation of dynophores. Features grouped into one superfeature
are saved in PML format for visualisation in LigandScout as 3D point clouds. Each
point cloud represents one superfeature, and is clickable in LigandScout. Each point in a
superfeature cloud represents one feature generated in one frame of the whole trajectory.
The point cloud shapes depend on the alignment chosen before DCD generation. The
superfeature point clouds can give an idea of the ligand-target dynamics over the tra-
jectory: a very compact cloud can represent a strong ligand-target interaction, a cloud
showing two different centres can point to distinct conformational changes during the
trajectory, and an areal cloud can indicate unspecific ligand-target interactions. In or-
der to concretise impressions from the spatial dynophore representation, statistical and
sequential information on superfeatures, and their interaction patterns are available. An
example is shown in Figure 3).
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Statistical information. Superfeatures are statistically described by the frequency of
their occurrence and by the frequencies of the occurrence of their interactions to the
environment: how often a superfeature is formed and how often a superfeature interacts
with which ligands can give rise to the importance of specific features and interaction
patterns (examples are shown in Figure 7 on page 24). Additionally, interactions are
statistically characterised by their distance, visualised as ligand-environment distance
histograms. This descriptor can be used for estimating feature quality and relevance (an
example is shown in Figure 10a on page 26).
Sequential information. Furthermore, all parameters used to gain statistical insights
into ligand-target dynamics are also monitored over the trajectory: occurrences of super-
features and their interaction partners (examples are shown in Figure 9 on page 25) as well
as interaction distances (an example is shown in Figure 10b on page 26). Hence, confor-
mational transitions and superfeature evolution as descriptor for ligand-target dynamics
can be easily accessed.
Dynophores give a dynamic view on ligand-target interactions by including flexibility
derived from MD simulations, and potentially enhance the predictive power of 3D phar-
macophores. With the interplay of spatial, statistical and sequential information about
ligand-target dynamics, dynophores provide a powerful analysis tool for the evaluation
of pharmacophore features, interaction patterns and MD simulations.
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Figure 3: Concept of dynophore generation with DynophoreApp. Dynophore-
App input: the user provides DynophoreApp with ligand-target definition and an MD
trajectory of the molecular system to be analysed in PMZ and DCD format, respectively.
Dynophore generation: DynophoreApp generates for each trajectory frame a Ligand-
Scout 3D pharmacophore and groups features into so-called superfeatures in terms of
feature type and involved atoms on ligand-site. Additionally, all interaction partners per
superfeature are saved. This dynamic pharmacophore is termed dynophore. Dynophore-
App output: DynophoreApp outputs a graphical representation of all features grouped
into superfeature as 3D point cloud each, and a statistical and sequential superfeature
and interaction pattern analysis.
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4 Implementation: DynophoreApp
In this study, DynophoreApp was implemented using the API of the ilib/LigandScout
framework that has been developed in the programming language Java. The implementa-
tion of the DynophoreApp program is presented from dynophore generation to analysis.
DynophoreApp uses the LigandScout molecular environment structure which is com-
posed of a core molecule and a macromolecule (Section 3.1). In the following, the core
molecule is referred to by the term ligand and the macromolecule by the terms target or
environment.
4.1 DynophoreApp: Dynophore Data Structure
Information about dynophores is stored in an object termed Dynophore whose data struc-
ture is presented in the following and summarised in Figure 4.
4.1.1 Dynophore Class
The Dynophore class contains ligand- and target-site related information for the detection
and analysis of interaction patterns. The Dynophore class inherits from the Pharmacophore
class (Section 2.2.2), and additionally contains
• a set of SuperFeature objects (TreeSet<SuperFeature> superFeatures) containing
all dynophore superfeatures, as well as
• the number of MD trajectory frames (int numFrames).
4.1.2 SuperFeature Class
The SuperFeature class describes a superfeature that is defined by a certain feature type
and by its involved atoms on ligand-site. Each superfeature is stored in one SuperFeature
object. On the one hand, this class contains ligand-site related information about a
specific superfeature, such as
• the superfeature type (String featureName), such as HBD, functioning as identifier
key,
• all atom serial integers on ligand-site which are associated with this superfeature
(ArrayList<Integer> involvedAtomsSerials), e.g. the oxygen serial of a hydroxyl
group involved in a HBD feature or several serials in case of an AR feature, func-
tioning as identifier key,
• a feature point cloud (ChemicalFeatureCloud3D chemicalFeatureCloud3D) grouping
all features from the whole MD trajectory which belong to this superfeature, and
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• the presence or absence of that superfeature in each trajectory frame as a boolean
expression (Boolean[] superFeatureEvents).
On the other hand, the SuperFeature class also contains target-site related information.
The interaction partners for a superfeature are monitored over the whole trajectory:
• each interaction (environmental) partner involved in this superfeature is stored in
an EnvPartner object, and saved as set in the SuperFeature class (Set<EnvPartner>
envPartners).
4.1.3 EnvPartner Class
The EnvPartner class describes one interaction partner on target-site over the whole
trajectory. EnvPartner is defined by the atom serials on target-site which are involved in
the superfeature. Each EnvPartner is stored in its associated SuperFeature object, and
contains the following information:
• all atom serials on target-site which are involved in the interaction (Set<Integer>
envPartnerSerials), functioning as identifier key,
• the name of the residue or component that contains the atom serials, e.g. LEU145
for a specific residue or PPS for a cofactor (String envPartnerName),
• the occurrence of the interaction leading to a feature in LigandScout as a boolean
expression (Boolean[] envPartnerEvents), and
• the distances between the geometric centres of the superfeature building atoms on
ligand-site and the interaction partner on target-site (float[] envPartnerDistances).
4.1.4 ChemicalFeatureCloud3D Class
The ChemicalFeatureCloud3D class describes all features over the whole trajectory which
are grouped into one superfeature. It inherits from the ChemicalFeature3D class (see
Section 2.2.2), and additionally contains
• the coordinates for the geometric centre of the feature cloud (Vector3f cloudPosition)
and
• all points belonging to this feature cloud in a list of AdditionalPoint objects
(ArrayList<AdditionalPoint> additionalPoints).
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4.1.5 AdditionalPoint Class
The AdditionalPoint describes one feature that belongs to a certain pharmacophore
generated in a certain trajectory frame, and that is grouped to a specific superfeature.
This class therefore consists of
• the coordinates for a feature cloud point which represent the geometric centre of all
atoms positions that are involved in this feature (Vector3f pointPosition), and
• the frame index to which the features belongs, in order to map each cloud point to
the trajectory (int frameIndex).
Dynophore
int numFrames
TreeSet< SuperFeature > superFeatures
String featureName
ArrayList<Integer> involvedAtomsSerials
Boolean[] superFeatureEvents
ChemicalFeatureCloud3D chemicalFeatureCloud3D
Vector3f cloudPosition
ArrayList< AdditionalPoint > additionalPoints
Vector3f pointPosition
int frameIndex
Set< EnvPartner > envPartners
String envPartnerName
Set<Integer> envPartnerSerials
Boolean[] envPartnerEvents
float[] envPartnerDistances
Figure 4: Dynophore data structure. DynophoreApp generates a dynophore in form
of a Dynophore object which contains all superfeatures in SuperFeature objects. Each
superfeature has a ChemicalFeatureCloud3D object that stores all associated features
as point clouds in AdditionalPoint objects. Additionally, each superfeature encloses all
interaction partners on target-site in EnvPartner objects. Grey boxes represent Java
classes with their class fields listed below.
15
4 IMPLEMENTATION: DYNOPHOREAPP
4.2 DynophoreApp: Program Workflow
The DynophoreApp subsequently invokes the classes DynophoreGenerator for dynophore
input and generation, and DynophoreAnalyser for dynophore analysis and output. Using
the method ChemicalFeaturePreferencesChanger, changes of the chemical feature pref-
erences such as hydrogen bond distances and angles for hydrogen bonds can be set before
dynophore generation and analysis.
4.2.1 DynophoreGenerator Class
DynophoreGenerator generates a Dynophore object from a PMZ and DCD input (Sec-
tion 3.1). The Dynophore object is initialised, and the method init() reads the molecu-
lar environment of the system defining core molecule and macromolecule from the PMZ
format as MoleculeEnvironment object, and all MD trajectory frames from the DCD for-
mat as DCDTrajectory object. The dynophore for that molecular system is generated by
successively processing all trajectory frames with the method processFrames(): for each
frame ti, the molecular environment MoleculeEnvironment is updated with the current
positions for all atoms of the system given in DCDTrajectory, and a structure-based 3D
pharmacophore is created for this setting. The pharmacophore generating method is a
core function of the ilib/LigandScout framework.
Subsequently, the method processPharmacophore iterates over each pharmacophore fea-
ture fj, and invokes the processFeature method processing information on ligand and
environmental site for each feature as follows:
1. The method addFeatureToDynophore generates a SuperFeature object from fea-
ture fj that is defined by its feature type featureName and its involved atom
serials on ligand-site involvedAtomsSerials. This SuperFeature object is com-
pared to all SuperFeature objects that are already assigned to the superfeature set
TreeSet<SuperFeature> superFeatures of the Dynophore object. (i) If this super-
feature already exists, information about the frame it occurred in, and the feature
fj position is added to the superFeatureEvents and ChemicalFeatureCloud3D fields
of the associated SuperFeature object. (ii) If the superfeature has not occurred
before, it is added to the set of superfeatures with all corresponding information
(Figure 4).
2. The method addEnvPartnersToDynophore considers all interaction partners of fea-
ture fj. For each interaction partner on the environmental site of feature fj, a
EnvPartner object is generated defined by its interacting atoms envPartnerSerials.
This EnvPartner is compared to all EnvPartner objects that are already in the set
Set<EnvPartner> envPartners of the Dynophore object. (i) If the environmental
partner is already in the set, information about the frame it occurred in is added to
the envPartnerEvents field of the associated EnvPartner. (ii) If the environmental
partner has not occurred before, it is added to the set of environmental partners
with all corresponding information (Figure 4).
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The method processEnvPartnerDistances is invoked after processing all frame pharma-
cophores with all their features. It iterates over all frames to save the distances of all
superfeature feature points to their environmental partners to envPartnerDistances of
the EnvPartner object.
4.2.2 DynophoreAnalyser Class
The DynophoreAnalyser covers the analysis of the generated dynophore as described in
the following.
Dynophore visualisation. The method writeDynophoreToPML writes information about
ChemicalFeatureCloud3D from the Dynophore object in PML format. This file format can
be loaded in the structure-based view of LigandScout for a graphical representation of
the dynophore. Examples: Figure 6, page 21.
Sequential superfeature and interaction occurrences. Occurrences of superfea-
tures and their interactions evolving over the MD trajectory (so-called sequential occur-
rence) are represented as multiple bar codes. These bar codes are plotted using the class
PlotBarCode in the methods plotSuperFeaturesBarCode and plotEnvPartnersBarCode:
The first method draws the occurrence of all dynophore superfeatures in a separate
subplot. The second draws for each superfeature a plot that shows the occurrence of in-
teractions with all its environmental partners in a separate subplot. Example: Figure 9,
page 25.
Statistical superfeature and interaction occurrences. The frequencies of the oc-
currence of superfeatures and their interactions (so-called statistical occurrences) are
saved as percentages.
Furthermore, interaction distance quality is sequentially and statistically visualised as
distance series and histogram, respectively.
Sequential interaction distances. The method plotEnvPartnersDistancesXYGraph
uses the PlotXYGraph class to create a plot for each superfeature showing all environ-
mental partner in a trajectory-distance plot. Additionally, every distance data point
that is associated with a superfeature is highlighted with a diamond-shaped marker.
Since a feature is not only defined by its distance between ligand and environment, this
marker provides additional information about the interaction type. Example: Figure 10b,
page 26.
Statistical interaction distances. The method plotEnvPartnersDistancesHistograms
creates for each superfeature a histogram from the PlotHistogram class that shows the
distance distribution for each environmental partner in one plot. The distance distri-
bution is only shown for those frames that provoke a feature. Example: Figure 10a,
page 26.
Data for sequential plots are preprocessed by the FramesDownsizer class that downsizes
the trajectory length to a user-defined length for appropriate graphical representation.
17
4 IMPLEMENTATION: DYNOPHOREAPP
Since a trajectory of 20,000 data points cannot be resolved properly in a graph of 500x500
pixel size, only 1,000 data points are used here. Data for bar code plots are merged, e.g.
20 frames to one, and assigned with occurrence (and frequency of occurrence) if half or
more frames have an occurrence (Figure 9). Data for the trajectory-distance plot are
not merged, but every e.g. 20th frame is used and represented with its information on
distance and occurrence, (Figure 10b).
All plotting classes use the Java package JFreeChart [24]. The dynophore plots are
currently saved as JPG files, and raw data from all Dynophore fields are saved as data
files for individual further processing.
DynophoreGenerator
readMoleculeEnvironment
readTrajectory
processFrames
processPharmacophoreFeatures
addFeatureToDynophore
addEnvPartnerToDynophore
processEnvPartnerDistances
DynophoreAnalyser
writeDynophoreToPML
plotSuperFeaturesBarCode
plotEnvPartnersBarCode
plotEnvPartnersDistancesXYGraph
plotEnvPartnersDistancesHistogram
writeData
PlotBarCode
PlotBarCode
PlotXYGraph
PlotHistogram
Figure 5: DynophoreApp workflow: Dynophore generating and analysing classes
DynophoreGenerator and DynophoreAnalyser are presented with their main methods.
Java classes are highlighted with grey boxes.
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5 Applications
In this section, several applications for dynophores are demonstrated. Dynophore analy-
ses can help the understanding of (i) ligand and feature dynamics, Section 5.1, (ii)
ligand-environment interaction patterns during MD simulations, Section 5.2, (iii) MD-
based feature importance in comparison with static pharmacophores, Section 5.3, and
(iv) differences in ligand-target interactions of similar ligands, Section 5.4. Dynophore-
App was tested on data from 100 ns MD simulations showing sulfotransferase SULT1E1
with cofactor phosphoadenosine-5’-phosphosulfonate (PAPS), and ligand kaempferol or
4-OH-2,3,5,2’,4’,5’-hexachlorobiphenyl (4-OH-HCB), Section 5.1 to 5.3. In Section 5.4,
dynophores are discussed for 50 ns MD simulations with muscarinic M2 acetylcholine re-
ceptor (M2AChR) in complex with ligand iperoxo or isoxazol. The MD simulations were
conducted by Christin Rakers and Marcel Bermudez, respectively, Institut fu¨r Pharmazie,
Freie Universita¨t Berlin.
Sulfotransferase SULT1E1. In phase II metabolism, sulfotransferases (SULT) regu-
late the sulfonation of endogenous and xenobiotic small molecules. The sulfonate group
of SULT cofactor PAPS is transferred to the hydroxyl group of the substrate. SULTs are
prone to inhibition by endo- or exogenous substances, leading to decreased sulfonation
rates and therefore disruptions of the homeostasis of endogenous substances. Thus, the
understanding of SULT is important for health risk assessment in drug discovery. Rakers
et al. [17] presented a novel ligand prediction model for SULT1E1. MD simulations based
on a crystal structure without ligand (PDB: 1HY3 [25]) were performed to sample protein
conformational space. Ensemble docking with a database containing active ligands was
used to generate ligand-protein docking poses. LigandScout 3D pharmacophores were
generated for eight selected ligands in selected poses, enabling the identification of active
ligands of SULT1E1 via virtual screening. In order to validate the pharmacophores, MD
simulations were performed for the selected docking poses with three runs each. In the
presented study, dynophores were generated and analysed for all MD simulations and are
representatively discussed for ligands kaempferol and 4-OH-HCB.
Muscarinic M2 acetylcholine receptor (M2AChR). Muscarinic receptor M2AChR
belongs to the superfamily of G protein coupled receptors (GPCRs) mediating cell re-
sponses to messengers such as hormones, neurotransmitters, light, and physical stimuli.
GPCRs have multiple integrative and highly dynamic signalling pathways including the
activation of G proteins, β-arrestin and G protein interacting proteins (GIPs). Due to the
broad ligand and signalling spectrum of GPCRs, a mechanistic understanding of ligand
binding is important in drug discovery. Bock et al. [26] compared experimentally shown
high differences in binding affinity for ligands iperoxo and isoxazol by performing and
analysing MD simulations based on docking poses from active M2AChR crystal structure
(PDB: 4MQT [27]). In the presented study, dynophores were generated and analysed for
both iperoxo and isoxazol MD simulations to help the understanding of ligand binding
differences from a dynamically view.
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5.1 Application: Dynophore Feature Space Analysis
The graphical representation of dynophores as 3D point clouds derived from MD sim-
ulations visualises ligand dynamics and feature distributions at a glance. The spatial
distribution of dynophore features can give a first idea about (i) ligand flexibility and
potential conformational states of the ligand within the active side, and (ii) ligand posi-
tioning, e.g. whether a ligand changes its initial MD position. Representative dynophores
are discussion for MD simulations with SULT1E1 in complex with cofactor PAPS and
kaempferol or 4-OH-HCB (Figure 6).
Dynophores for two different MD simulations with SULT1E1 in complex with PAPS
and kaempferol show different feature distribution types. The dynophore derived from
the first simulation is shown in Figure 6a. Well-shaped spheric feature point clouds
with scarce outliers resemble the pharmacophore feature spheres in shape and diameter
(Figure 2). Analysis of the associated MD trajectory shows stable ligand positioning in
the docking pose used as simulation starting structure. However, a second simulation
for the same ligand-target complex results in a differently shaped dynophore presented
in Figure 6b. This dynophore shows an areal point distribution moving away from the
initial ligand position, and several spheric point clouds slightly shifted away from the
initial ligand position. Investigations on the associated MD simulation revealed that at
the beginning of the simulation, the ligand slightly changes its starting position where
it was positioned stably for 17,000 frames, represented in the dynophore with spheric
point clouds. Afterwards, it moves away from the active side centre, indicated in the
dynophore with the areal feature regions.
As a third example, the dynophore for an MD simulation of SULT1E1 in complex with
PAPS and 4-OH-HCB is presented in Figure 6c. The ligand consists of two chloride
containing phenyl rings connected by a single bond. One ring contains four chlorides
and a hydroxyl group pointing to PAPS in the active side centre. The dynophore shows
spheric point clouds for the HBD and HBA feature of the hydroxyl group and for four H
features of the four chloride atoms. The dynophore for the second ring pointing towards
the active side opening shows three H features for its three chloride ions as broad banana-
shaped feature clouds. Investigations on the underlying MD simulation revealed that the
ring pointing to the active side centre is rather inflexible, whereas the ring pointing to
the active side opening is flexibly rotating along the single bond connecting both rings.
Thus, with the graphical representation of dynophores showing feature distributions in
space, ligand flexibility as well as small or big changes in ligand positioning and inter-
action can be very easily accessed as a starting point for detailed and individual MD
trajectory analysis.
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Figure 6: Graphical representation of dynophores as spatial point clouds.
Dynophores derived from MD simulations of SULT1E1 in complex with PAPS and the
following ligands: (a) rather inflexible kaempferol, (b) flexible kaempferol moving away
from the active side, and (c) 4-OH-HCB having an inflexible and a rotating moiety to-
wards the active side centre and opening, respectively. All dynophores are presented
with ligands (conformation of first trajectory frame). All ligands are positioned with the
active side centre containing cofactor PAPS to the left and the active side opening to the
right.
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5.2 Application: MD-based Interaction Pattern Analysis
DynophoreApp provides comprehensive information about the interaction pattern be-
tween ligand and its environment. The occurrence of a superfeature and the occurrence
of its interactions to different environmental partners are described statistically as occur-
rence percentages, as well as sequentially as occurrence bar code plots. Furthermore, the
interaction quality is described by interaction distances: statistics and trajectory moni-
toring for data on all interaction partners for one superfeature are assessable as distance
histograms and trajectory-distance series, respectively.
The interaction pattern analysis is presented using SULT1E1 in complex with cofactor
PAPS and kaempferol as an example. The interaction pattern in Figure 7 presents eight
superfeatures different in their frequencies of occurrence, showing only those greater than
5%. Whereas the AR feature occurs only in 19% of the whole simulation, the hydroxyl
group pointing to the active side centre occurs in 74% of the trajectory as HBD feature
interacting with the catalytic His105 (65%) and the sulfonate oxygen atoms of the cofac-
tor PAPS (31%, 30% and 12%). The associated ring has an H feature interacting over
the whole trajectory (100%) with mainly aromatic amino acids such as phenylalanine
and tyrosine. The ligand moiety pointing to the active side opening is among others
stabilised by a hydroxyl group interacting with Asp20. Thus, the dynophore is in agree-
ment with the reported interaction pattern at the catalytic centre of SULT involving the
His105 induced transfer of the sulfonate group from PAPS to the catalytically important
hydroxyl group of the ligand kaempferol [28].
Furthermore, the interactions of the hydroxyl group of kaempferol to the active side centre
shown in Figure 8 were exemplary analysed in more detail. The sequential bar code plot
shows an evenly distributed superfeature occurrence which is in 65% of the frames based
on interactions with His105, and in 73% of the frames based on interactions with the
PAPS sulfonate oxygen atoms (Figure 9). In the beginning of the MD simulation, the
hydroxyl group of the ligand interacts with His105 (red) and one of the PAPS sulfonate
oxygen atoms (green). A dynamic interplay of the ligand with His105 and the PAPS
sulfonate group develops over the trajectory as shown in the interaction partner bar
code plots: Single hydrogen bonds to either His105 or PAPS, and bifurcated hydrogen
bonds to both are observed. The rotatable sulfonate group allows alternating interaction
intervals for each of the three oxygen atoms with preference to two of them (green and
cyan).
Interaction distance analyses give further insight into the interaction quality (Figure 10).
The interaction distance histogram in Figure 10a shows the distribution for all frames
that show a superfeature for the hydroxyl group of the ligand. The different percentages
of occurrence discussed before result in different distribution peak areas. The distance
distribution of His105 shows one sharp peak at hydrogen bonding distance around 2.8 A˚.
However, the distance distributions of all three PAPS sulfonate oxygen atoms show two
peaks, one small peak at short hydrogen bonding distance of around 2.6 A˚, and one large
peak at larger distances. On the basis of distance analysis, ligand hydrogen bonding to
His105 seems of higher quality (strength), whereas hydrogen bonding to PAPS mainly
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shows weaker hydrogen bonds (higher distance peak) and only some stronger hydrogen
bonds (lower distance peak). Hence, even though the amount of hydrogen bonds estab-
lished to His105 and PAPS is similar, the interaction quality seems higher for His105.
Interaction distance trajectory series in Figure 10b shows all interaction distances over
the trajectory with a diamond-shaped marker indicating superfeature occurrence in the
marked trajectory frame. This plot can be useful to detect major changes in the inter-
action conformation. For instance, a large change of interaction distances or switches
between two different distance values during the simulation indicates conformational
changes. Findings like these represent a good starting point for further investigations
of specific trajectory intervals and is therefore a helpful additional MD analysis tool to
handle large MD trajectories. In the example shown here, only short minor changes in
the interaction distances to PAPS are observed.
All in all, dynophores serve as a powerful MD analysis tool for the assessment of inter-
action patterns and their interaction quality. Statistics help to give an overview over
superfeatures and their interactions. Sequential analysis provide access to trajectory
clusters or unexpected events during the trajectory for further targeted analysis.
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Figure 10: Dynophore analysis: interaction distances in form of (a) a distance
histogram for all frames with the superfeature present, as well as (b) a sequence over the
trajectory with diamond-shaped markers at frames with superfeature present. Interaction
partners for the catalytic hydroxyl group of kaempferol (superfeature HBD) are His105
in red, and sulfonate oxygen atoms of PAPS in blue, green and cyan. See Figure 8 for
structural arrangement of the active side.
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5.3 Application: Validation of Static Pharmacophores
Pharmacophores not only provide a compact view on ligand interactions, their 3D fea-
ture arrangement is also used for virtual screening to find structurally similar ligands that
could bind to the same target. Pharmacophore features are optimised via virtual screen-
ing against a training set of active and inactive ligands. The same procedure is possible
with dynophores but not yet implemented. However, dynophores already can be used to
validate or optimise static pharmacophore models, since the additional information on
dynamics can help to weight pharmacophore features. Statistics on the occurrence of a
superfeature are referred to as frequency in the following.
The static pharmacophore shown in Figure 11a was derived from a default pharmacophore
generation in LigandScout on the basis of a selected SULT1E1 docking pose with cofactor
PAPS and ligand kaempferol, and a subsequent pharmacophore optimisation with virtual
screening against a database of active and inactive ligands [17]. The optimised pharma-
cophore consists of five features, two HBD features, an H feature and two AR features.
A dynophore is derived from an MD simulation of a docking pose with kaempferol.
The obtained dynophore (Figure 11b) resembles only those superfeatures assigned in the
static pharmacophore. Their frequencies give an idea of the importance of each feature
based on the underlying MD simulation. Both HBD features (72% and 94%) and the H
feature (100%) are confirmed with high feature frequencies, whereas both AR features
showed only low frequencies (19% and 1%). The dynophore in Figure 11c shows all
superfeatures with a frequency higher than 5%, and reveals some additional superfeatures
in contrast to the static pharmacophore. Both pharmacophore HBD features could also
serve as HBA (73% and 75%), and two additional minor HBD features are observed with
negligible occurrence (29% and 10%).
On the basis of these dynophore data, the static pharmacophore features could be dis-
cussed and revised if applicable. The frequencies of the dynophore features confirm on
the one hand both HBD features and the H feature present in the static pharmacophore,
but on the other hand suggest to omit both AR features. Furthermore, the dynophore
suggests that both HBD features also serve as HBA features. Interaction pattern analy-
sis shows that these two HBA features interacted with the Lys103 side chain and the
amide of the Asp20 peptidyl bond, respectively. Compared to their HBD counterparts,
which interact with the catalytic moieties PAPS and His105, and with the Asp20 side
chain, respectively, the HBD features seem of higher importance than the HBA features.
Hence, the dynophore analysis suggests the HBD features and the H feature present in
the static pharmacophore as core features. For higher specificity, the 19% AR feature
and both HBA features could be all or selectively included as mandatory or optional
features. Various combinations of core and additional features could be tested via virtual
screening against a database with active and inactive ligands to find the optimal feature
combination which is highly depending on the biology of the target.
As a future prospect, dynophores themselves could be used for virtual screening using
the feature frequency and distribution as matching criteria, read also Section 7.
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5.4 Application: Comparative Feature Frequency Analysis
The ligand iperoxo shows high affinity for muscarinic receptors due to optimally posi-
tioned chemical features (Figure 12a, left): the hydrophobic triple bond stabilises the
distance between the positively charged nitrogen and the 5-membered ring system con-
taining an oxygen as HBA. However, the introduction of an aromatic ring system in isox-
azol (Figure 12a, right) leads to a 100-fold lower binding affinity. Bock et al. [26] propose
that the affinity difference can be explained by qualitative differences in the strength of
hydrogen bonding between Asn404 and the oxygen in the ring systems, since furan-like
systems like isoxazol build weaker hydrogen bonds [29]. Pharmacophore analysis shows
no difference in ligand features and therefore can not explain the pharmacological data
(Figure 12a). In order to access the difference dynamically, MD simulations for iperoxo
and isoxazol bound systems were conducted and feature-wise analysed with dynophores
due to hydrogen bond geometries between Asn404 and the ring oxygen of iperoxo and
isoxazol, respectively.
Dynophores for the simulation of iperoxo and isoxazol bound to M2AChRs are presented
in Figure 12b. Spheric features confirm a stable ligand positioning with a favourable dis-
tance between the oxygen of the ring system (HBA feature) and the positively charged
nitrogen (PI feature), linked via the triple bond (H feature). Furthermore, the H and
PI features occur permanently during the simulations interacting with the same envi-
ronmental partners. However, the simulations shows differences in the occurrence of the
HBA feature at their ring oxygen: the dynophore analysis for iperoxo shows hydrogen
bonding to Asn404 almost permanently in all frames (98%), whereas the interaction is
formed only in 87% of all frames during the trajectory of isoxazol.
Dynophore-based sequential analysis shows that the HBA feature is evenly distributed
over the whole trajectory for both iperoxo and isoxazol, in contrast to a permanent dis-
ruption of the feature during the trajectory. Thus, the lower frequency for HBA in case
of isoxazol suggests a continuous lower hydrogen bond strength. Hence, further analysis
on distances and angles characterising the hydrogen bond quality were conducted. Hy-
drogen bond distances are defined by the distance between the HBD and HBA atom,
and hydrogen bond angles by the angle formed by the HBD, the hydrogen and the HBA
atom. The stronger the hydrogen bond is, the shorter distances and the smaller (= more
linear) angles exist [30]. The results show that iperoxo forms hydrogen bonds more often
with shorter distances and smaller angles than observed in isoxazol, suggesting stronger
hydrogen bonding in case of iperoxo (Figure 12c). The profound difference in affinity
between iperoxo and isoxazol might at least partially be explained by the structural
differences in hydrogen bonding of the oxygen in the rings systems as revealed by the
dynophore analysis.
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6 Discussion
Dynophores represent a novel approach of pharmacophore modelling that includes con-
formational flexibility of a molecular system derived from MD simulations without prior
clustering or other preprocessing. Thus, dynophores represent the dynamics of a molec-
ular system including all frames of the MD trajectory, and can therefore not only be
applied to dynamic pharmacophore modelling but also to MD-based interaction pattern
analysis.
In the following, limitations of the dynophore concept, and applications for the Dynophore-
App analysis output are discussed.
6.1 Dynophore Limitations
When analysing and discussing dynophores, two main limitations must be considered:
the DynophoreApp output is highly depending on the LigandScout feature definitions on
the one hand, and on the MD simulation on the other hand.
LigandScout feature definitions. The dynophore, as any other pharmacophore ap-
proach, represents human-defined features that are thought to represent natural chemical
properties. Whether the program sets a feature or not is defined by thresholds that are
set carefully but artificially with LigandScout chemical feature definitions. Therefore, a
sophisticated understanding of the feature definitions, and a careful examination of fea-
ture quality instead of relying only on the on/off information about features is crucial for
the dynophore analysis. DynophoreApp provides an analysis of interaction distances for
the assessment of interaction quality to give a first overview of the trajectory evolution.
Further tools could be implemented such as interaction angle or binding energy analysis.
MD trajectory sampling. Dynophores aim to extend pharmacophore models with
information about conformational space sampling derived from MD simulation. The
quality of conformational space sampling in an MD trajectory determines the signifi-
cance and statistical power of the associated dynophore. However, if a simulation shows
a large population of one conformation, the conformation is not necessarily more impor-
tant than others. For instance, the molecular system might simply be trapped in the
energy landscape of that conformation, not able to sample other evenly or even more
important conformational states. However, DynophoreApp will statistically analyse the
trajectory and assign high weights to the superfeatures of that sampled conformation,
suggesting high importance. Another simulation might relativise this statement due to a
different conformational sampling. Many MD methods that more comprehensively assess
conformational space are developed such as Markov state modelling or scaled MD [31, 32].
Therefore, it is important that the DynophoreApp user only utilises representative MD
simulations for dynophore analysis, especially when arguing with dynophore statistics.
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MD trajectory alignment. Dynophore superfeatures are graphically represented as
spatial point clouds. The point cloud shapes are depending on the interaction dynamics
of ligand and environment in the underlying MD simulation, see Section 5.1. However,
the shape is also highly depending on the MD trajectory alignment conducted during
the preprocessing of the DCD input file, see Section 2.3.2. Two different alignments,
such as the alignment of the whole protein or of only the active side, will generate two
different graphical representations of the dynophore. However, the statistical and sequen-
tial analysis is alignment-independent, since the analysis summarises all independently
processed frames.
6.2 Dynophore Applications
Considering the discussed limitations and interpretation pitfalls, dynophores provide a
widespread analysis tool for the assessment of conformational space and interaction pat-
tern including spatial, statistical and sequential information. Potential applications for
dynophores shown in this work include:
1. The graphical representation of dynophores showing feature distributions in space
allow the easy assessment of ligand flexibility as well as small or big changes in
ligand positioning and interaction. The results from such an analysis can be a
starting point for detailed and individual MD trajectory analysis. (Section 5.1)
2. Dynophores serve as a powerful MD analysis tool for the investigation of interaction
patterns and their interaction quality. DynophoreApp provides (i) statistics to give
an overview on the distribution of superfeatures and interaction patterns, and (ii)
analysis of the trajectory sequence to access trajectory clusters or unexpected events
during the trajectory for further detailed analysis. (Section 5.2)
3. Dynophores can be used to validate or optimise static pharmacophore models, since
the additional information on dynamics can help to weight pharmacophore features.
(Section 5.3)
4. Furthermore, dynophore can give access to differences in ligand-target interactions
for very similar ligands that show no binding differences with conventional static
pharmacophores. (Section 5.4)
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7 Conclusion and Future Prospects
The aim of this study was to develop pharmacophore models that include the confor-
mational space of a molecular system derived from MD simulations. These dynamic
pharmacophore models were implemented as dynophores in form of the DynophoreApp
program using the API of the ilib/LigandScout framework. DynophoreApp is a compre-
hensive MD analysis tool with integrated pharmacophore definitions from LigandScout.
The program groups features reoccurring over an MD trajectory into superfeatures, and
provides an automated spatial, statistical and sequential analysis of their occurrence and
interaction patterns.
Dynophores enrich classic static pharmacophores with information about the flexibil-
ity and conformational space of a molecular system. Therefore, dynophores potentially
enhance the predictive power of pharmacophores and serve as helpful tool for the analy-
sis of MD-based interaction patterns. Dynophore applications include (i) feature space
analysis for the assessment of ligand-target flexibility, (ii) studies on MD-based interac-
tion patterns, (iii) validation and improvement of static pharmacophores, as well as (iv)
investigations on the importance of pharmacophore features for similar ligands.
Dynophores are applicable to diverse assignments at the intersection of pharmacophore
modelling and MD simulation analysis. Hence, several future projects based on in this
study implemented data structure for dynophores are of interest: (i) implementation of
virtual screening with dynophores to potentially enhance virtual screening results, (ii)
representation of the superfeature clouds as density function for further superfeature
space analyses, and (iii) implementation of interaction angle analysis complementing the
implemented interaction distance analysis for further assessment of interaction quality.
Furthermore, dynophores are planned to be integrated more closely in the proprietary
ilib/LigandScout software package and to be made publicly available.
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A Appendix
LigandScout term Definition
molecular environment LigandScout interpretation of a system consisting of a
core molecule, a macromolecule and optionally a phar-
macophore
core molecule molecular environment assigned as ligand in a structure-
based approach
macromolecule molecular environment assigned as target in a structure-
based approach
HBA feature hydrogen bond acceptor (3D pharmacophore feature)
HBD feature hydrogen bond donor (3D pharmacophore feature)
H feature hydrophobic area (3D pharmacophore feature)
AR feature aromatic ring (3D pharmacophore feature)
PI feature positive ionisable (3D pharmacophore feature)
NI feature negative ionisable (3D pharmacophore feature)
Table A.1: LigandScout terminology. This table presents a short definition for main
LigandScout terms.
Dynophore term Definition
superfeature all pharmacophore features that reoccur over the whole
trajectory with the same feature type and the same in-
volved atoms on ligand-site
dynophore ensemble of all superfeatures for one core molecule
core molecule molecule whose interaction properties are of interest,
mostly a ligand, see Table A.1
environmental partner molecular environment that is potentially interacting with
the core molecule, including e.g. target, cofactors, water,
ions
superfeature point cloud spatial representation of all features over the trajectory
grouped into one superfeature as points
spatial analysis analysis of the superfeature point cloud distribution
statistical analysis analysis of the frequency of a property during the whole
trajectory
sequential analysis analysis of the evolution of a property for the sequence of
system conformations over the trajectory
Table A.2: Dynophore terminology. This table presents a short definition for dyno-
phore terms that are introduced in this study.
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